|Bid||180.20 x 1300|
|Ask||180.24 x 1100|
|Day's Range||174.84 - 180.83|
|52 Week Range||144.75 - 199.85|
|Beta (3Y Monthly)||1.04|
|PE Ratio (TTM)||19.30|
|Earnings Date||Apr 23, 2019|
|Forward Dividend & Yield||2.08 (1.05%)|
|1y Target Est||197.67|
Looking at Stryker Corporation's (NYSE:SYK) earnings update in December 2018, analyst consensus outlook appear pessimistic, with...
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine along with an upbeat 2019 view are likely to support Stryker (SYK) in Q1. But integration risks might be a dampener.
Stryker (SYK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.
Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.
The outcomes of the study demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Resmed's (RMD) Brightree ReSupply is a scalable and automated solution that comprises live-agent inbound and outbound calls for more private interaction with patients and email reminder capabilities.
This joint venture marks Walgreens' (WBA) commitment toward enabling access to affordable healthcare and creating neighborhood health destinations.
The outcomes of the study, conducted by Medtronic (MDT), demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Varian Medical (VAR) announces the installation of cyclotron for its ProBeam proton therapy system at the Hefei Ion Medical Center in China.
Walgreens Boots (WBA) currently endeavors to redress certain areas of operational weakness and reinforces its managerial competence to drive operating efficiency with a resolute focus.
Medtronic's (MDT) Guardian Connect system can now be accessed via a Blue Cross and Blue Shield of Minnesota member's pharmacy benefit.
The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.
Intersect ENT (XENT) recently finishes the ENCORE Study, which is a small 50-patient open label program, designed to evaluate the safety of the repeat use of SINUVA.
Per Natus Medical (BABY), this deal is strategically aligned with its business as besides concentrating on its core products, this sell-off will lead to planned investment in the high-growth markets.
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
The primary goal of the study was to assess the safety and efficacy of Orthofix's (OFX) M6-C artificial cervical disc in comparison to ACDF treatment.